Included were adults with type 2 diabetes taking semaglutide, other GLP-1 drugs (dulaglutide, exenatide) or non-GLP-1 receptor medications (empagliflozin, sitagliptin, glipizide) from December 2017 to December 2023
Effective management of GLP-1 agonist-related gastrointestinal effects requires a systematic approach combining patient education, lifestyle modifications, and appropriate clinical interventions
Recalls & Warnings June 16, 2004 Ads for Various Diet Pills and Topical Gels Dont Cut the Fat, Says the FTC On June 16, 2004, The Federal Trade Commission (FTC)charged a Utah-based company, five related corporations, and three individuals operating as a common enterprise with making numerous false and unsubstantiated claims for weight-loss and fat-loss gels and supplements
Take two (2) capsules daily with food and 68 oz of water
For example, one clinical trial reported that 15.2 percent of participants experienced headaches after higher-dose semaglutide, compared to 12.2 percent of participants receiving a placebo (an inactive treatment)
